Arcturus Therapeutics Inc. announced it has raised $1.3 million in seed funding from a network of private investors in the U.S. and Canada.

The company, which is being incubated at the Janssen Labs Life Science Innovation Center in La Jolla, uses RNA interference technology — creating ways to interrupt the development disease-causing genes.

The company said its aim is to develop treatment for rare diseases, though it hasn’t disclosed any specific targets.

— SDBJ Staff Report